Alnylam To Showcase Latest Data From TTR Franchise And Hypertension Program At American Heart Association Scientific Sessions 2024
Portfolio Pulse from Benzinga Newsdesk
Alnylam Pharmaceuticals will present data from its transthyretin amyloidosis and hypertension programs at the AHA Scientific Sessions 2024. Key presentations include findings from the HELIOS-B Phase 3 study of vutrisiran and interim results from a Phase 1 study of ALN-TTRsc04, as well as a new analysis of the KARDIA-1 Phase 2 study of zilebesiran.
October 30, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alnylam Pharmaceuticals will present significant data from its TTR and hypertension programs at the AHA 2024, including results from the HELIOS-B and KARDIA-1 studies.
The presentation of data from the HELIOS-B Phase 3 study, which achieved all endpoints, and the KARDIA-1 Phase 2 study at a major conference like AHA 2024 is likely to positively impact Alnylam's stock. Successful data presentations can enhance investor confidence and potentially lead to stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100